Cancer on motors: How kinesins drive prostate cancer progression?

Abstract

Prostate cancer causes numerous male deaths annually. Although great progress has been made in the diagnosis and treatment of prostate cancer during the past several decades, much about this disease remains unknown, especially its pathobiology. The kinesin superfamily is a pivotal group of motor proteins, that contains a microtubule-based motor domain and features an adenosine triphosphatase activity and motility characteristics. Large-scale sequencing analyses based on clinical samples and animal models have shown that several members of the kinesin family are dysregulated in prostate cancer. Abnormal expression of kinesins could be linked to uncontrolled cell growth, inhibited apoptosis and increased metastasis ability. Additionally, kinesins may be implicated in chemotherapy resistance and escape immunologic cytotoxicity, which creates a barrier to cancer treatment. Here we cover the recent advances in understanding how kinesins may drive prostate cancer progression and how targeting their function may be a therapeutic strategy. A better understanding of kinesins in prostate cancer tumorigenesis may be pivotal for improving disease outcomes in prostate cancer patients.

• Authors: Jia-Ming Wang, Feng-Hao Zhang, Zi-Xiang Liu, Yi-Jie Tang, Jiang-Feng Li, Li-Ping Xie
• Journal: Biochemical pharmacology (Biochem Pharmacol) Vol. 224 Pg. 116229 (Jun 2024) ISSN: 1873-2968 [Electronic] England
• PMID: 38643904 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2024 Elsevier Inc. All rights reserved.

Topics

• Humans
• Kinesins (metabolism, genetics, physiology)
• Male
• Prostatic Neoplasms (metabolism, pathology)
• Disease Progression
• Animals